

In the claims

1-45 (canceled).

46 (currently amended). A method for treating a fibrotic disease comprising administering to a patient having a fibrotic disease a therapeutically effective amount of a composition comprising a pharmaceutically acceptable carrier and a polypeptide comprising SEQ ID NO: 2, SEQ ID NO: 5 or SEQ ID NO: 7 or a salt thereof, wherein said fibrotic disease is lung fibrosis or liver fibrosis.

47 (previously presented). The method according to claim 46, wherein the fibrotic disease is lung fibrosis.

48 (previously presented). The method according to claim 46, wherein the polypeptide is glycosylated at one or more sites.

49 (previously presented). The method according to claim 46, wherein the polypeptide comprising SEQ ID NO: 2 is a fusion protein.

50 (previously presented). The method according to claim 49, wherein the fusion protein comprises an immunoglobulin Fc region fused to SEQ ID NO: 2.

51-54 (canceled).

55 (previously presented). The method according to claim 46, wherein the polypeptide consists of SEQ ID NO: 2.

56 (canceled).

57 (previously presented). The method according to claim 46, wherein the composition further comprises an interferon.

58 (previously presented). The method according to claim 57, wherein the interferon is interferon- $\beta$ .

59 (previously presented). The method according to claim 46, wherein a composition comprising an interferon is administered to said patient simultaneously, sequentially, or separately with a composition comprising a pharmaceutically acceptable carrier and SEQ ID NO: 2.

60 (previously presented). The method according to claim 46, wherein said fibrotic disease is liver fibrosis.

61 (previously presented). The method according to claim 46, wherein said composition comprises a pharmaceutically acceptable carrier and a polypeptide comprising SEQ ID NO: 2.

62 (previously presented). The method according to claim 46, wherein said composition comprises a pharmaceutically acceptable carrier and a salt of a polypeptide comprising SEQ ID NO: 2.

63 (previously presented). The method according to claim 62, wherein said salt is a sodium, calcium, ammonium, ferric or zinc salt.

64 (previously presented). The method according to claim 62, wherein said salt is a triethanolamine, arginine, lysine, piperidine or procaine salt.

65 (previously presented). The method according to claim 62, wherein said salt is an acid addition salt.

66 (currently amended). The method according to claim 65, wherein said acid addition salt is formed by the addition of hydrochloric, sulfuric, acetic or oxalic acid.

67 (new). The method according to claim 46, wherein said polypeptide comprising SEQ ID NO: 5 is a fusion protein.

68 (new). The method according to claim 67, wherein the fusion protein comprises an immunoglobulin Fc region fused to SEQ ID NO: 5.

69 (new). The method according to claim 46, wherein the polypeptide consists of SEQ ID NO: 5.

70 (new). The method according to claim 46, wherein said polypeptide comprising SEQ ID NO: 7 is a fusion protein.

71 (new). The method according to claim 67, wherein the fusion protein comprises an immunoglobulin Fc region fused to SEQ ID NO: 7.

72 (new). The method according to claim 46, wherein the polypeptide consists of SEQ ID NO: 7.

73 (new). The method according to claim 46, wherein a composition comprising an interferon is administered to said patient simultaneously, sequentially, or separately with a composition comprising a pharmaceutically acceptable carrier and SEQ ID NO: 5.

74 (new). The method according to claim 46, wherein a composition comprising an interferon is administered to said patient simultaneously, sequentially, or separately with a composition comprising a pharmaceutically acceptable carrier and SEQ ID NO: 7.

75 (new). The method according to claim 46, wherein said composition comprises a pharmaceutically acceptable carrier and a polypeptide comprising SEQ ID NO: 5.

76 (new). The method according to claim 46, wherein said composition comprises a pharmaceutically acceptable carrier and a polypeptide comprising SEQ ID NO: 7.

77 (new). The method according to claim 46, wherein said composition comprises a pharmaceutically acceptable carrier and a salt of a polypeptide comprising SEQ ID NO: 5.

78 (new). The method according to claim 77, wherein said salt is a sodium, calcium, ammonium, ferric or zinc salt.

79 (new). The method according to claim 77, wherein said salt is a triethanolamine, arginine, lysine, piperidine or procaine salt.

80 (new). The method according to claim 77, wherein said salt is an acid addition salt.

81 (new). The method according to claim 80, wherein said acid addition salt is formed by the addition of hydrochloric, sulfuric, acetic or oxalic acid.

82 (new). The method according to claim 46, wherein said composition comprises a pharmaceutically acceptable carrier and a salt of a polypeptide comprising SEQ ID NO: 7.

83 (new). The method according to claim 82, wherein said salt is a sodium, calcium, ammonium, ferric or zinc salt.

84 (new). The method according to claim 82, wherein said salt is a triethanolamine, arginine, lysine, piperidine or procaine salt.

85 (new). The method according to claim 82, wherein said salt is an acid addition salt.

86 (new). The method according to claim 85, wherein said acid addition salt is formed by the addition of hydrochloric, sulfuric, acetic or oxalic acid.